Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Detailed Description
-----------------
The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough. All study participants underwent full clinical evaluation including duration of fever, cough, dyspnea, anosmia or GIT symptoms, C-reactive protein (CRP), serum ferritin, D-dimer, Complete blood count (CBC), non-contrast chest computed tomography (CT) which was repeated 2 weeks after the start of treatment. The Azithromycin group included, 107 patients, mean age 45.8 ±18 years, 73 male and 34 female, the Clarithromycin group included 99 patients mean age 46.1±19 years, 68 males and 31 female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28 female.

Official Title
-----------------
Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: Clarithromycin 500mg
* Drug: Azithromycin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 cases Oxygen saturation > 93% Age >18 years Exclusion Criteria: Patients <18 years, patients with Oxygen saturation < 93%, patients with Diabetes mellitus or heart failure, patients on chemotherapy or immunosuppressive therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: clarithomycin group Azithromycin group control group
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: clarithromycin<br>clarithromycin group | Drug: Clarithromycin 500mg<br>* clarithromycin 500<br>* Other names: active;|
| Active Comparator: Azithromycin<br>azithromycin group | Drug: Azithromycin<br>* azithromycin group<br>* Other names: active comparison;|
| Placebo Comparator: control<br>control group | Drug: Placebo<br>* control group<br>* Other names: control group;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to fever control | time to complete resolution of fever | 15 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PCR conversion | time to PCR conversion from first positive PCR for COVID-19 to negative PCR | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Azithromycin, clarithromycin, COVID-19